27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
To assess whether home health agencies incur significantly higher care delivery costs for patients with cognitive impairment across three timeframes relevant to home health payment policy. 2 key findings →
Participants: 1,214 Evidence: low
Full summary, score breakdown and related studies → Original source
This Viewpoint discusses the Wasteful and Inappropriate Service Reduction (WISeR) model, a new payment model announced by the Centers for Medicare & Medicaid Services Innovation Center to broaden prior authorization in traditional Medicare. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cross-sectional study examines trends in coverage of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide, and prior authorization requirements among Medicare Part D beneficiaries. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multiple challenges were encountered in creating a sampling framework and contacting, recruiting and retaining care homes in the PACE study. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among beneficiaries sampled by CAHPS, 22.2% with ADRD completed the survey compared to 38.5% without ADRD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four themes were found: sense of self, connection to others, acceptance versus resistance in the face of adversity, and orientation toward the future versus focus on the present. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study population consisted of 54 million Medicare data Fee-for-Service (FFS) and Medicare Advantage enrollees aged ≥ 65; 5.3 million beneficiaries were diagnosed with ADRD, and 16.2% (n = 861,337) of beneficiaries diagnosed with ADRD resided in rural America. 4 key findings →
Participants: 861,337 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Those who reached the DBT in both years had higher morbidity and utilization. 4 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia is an incurable disease. The most promising advances in treatment include cholinesterase inhibitors and memantine. 1 key finding →
Design: cohort study Participants: 35,102 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Before the COVID-19 pandemic, supply and demand forcast models predicted significant nursing shortages across the United States through 2030 due to both an aging patient population and nursing workforce.1, 2 However, during the pandemic, we saw an exodus of younger nurses in addition to early retirements. 5 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The simulated cohort was informed by 111 600 PWH enrolled in Medicare at the start of 2026 (mean [SD] age, 70.9 [5.0] years; 77% male). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Structural brain imaging is guideline-recommended for cases with newly diagnosed cognitive impairment. 2 key findings →
Design: cross-sectional Participants: 1,095,947 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As disease-modifying therapies for Alzheimer's disease become available, ensuring equitable access to timely and accurate diagnosis of cognitive impairment is critical. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau deposition, impaired glucose metabolism, neuroinflammation, mitochondrial dysfunction, insulin resistance, and progressive brain atrophy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We aimed to explore primary care physicians' (PCP) attitudes, perceptions, and barriers toward Alzheimer's disease (AD) diagnosis and incorporating blood biomarker (BBM) tests into the diagnostic workflow. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reimbursement decisions for new Alzheimer's disease (AD) treatments are informed by economic evaluations. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Medical coding impacts patient care quality, payor reimbursement, and system reliability through the precision of patient information documentation. 3 key findings →
Participants: 487,775 Evidence: low
Full summary, score breakdown and related studies → Original source
The percentage of new enrollees with an ADRD code dropped significantly during the months of IMPACT passage (-1.42 percentage points; 95% CI, -2.13 to -0.71) and implementation (-1.98 percentage points; 95% CI, -2.70 to -1.26) but rose again during the following months. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Whilst nursing home managers recognise the potential benefits of advance care planning, barriers and challenges create a reluctance to facilitate. 3 key findings →
Participants: 178 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In AD, the presence of a lifetime history of depression corresponds to increases in AD-related neuropathological changes within the hippocampus. 4 key findings →
Participants: 52 Evidence: low
Full summary, score breakdown and related studies → Original source
Confusion and agitation in elderly patients are crucial problems. 1 key finding →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
Prevalence rates of neuropsychiatric symptoms in Dutch nursing home patients with dementia residing in SCUs are high, especially agitation and apathy. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Despite the limitation of a cross-sectional design, our initial findings suggest that there is a strong association between medical comorbidity and cognitive status in AD. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
PRE2DUP method gives highly accurate drug use periods for most drug classes, especially those meant for long-term use. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This article estimates the prevalence and identifies risk factors of resident aggression and abuse in assisted living facilities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →